SUBSCRIBE
SUBSCRIBE

Phase 2

Novartis Unloads Former New York Space for $18 Million, Resold for $30 Million
Drug Development
Novartis AG’s Phase III Drug for Heart Failure Bombs Trial
March 22, 2017
 · 
3 min read
3 Biotechs That Could be Taken Out This Quarter
Drug Development
5 Biotechs That Have Major Catalysts Coming in the Next 6 to 9 Months
March 22, 2017
 · 
3 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Drug Development
How This Drug Candidate Could be a Winner in Gilead’s Pipeline
March 21, 2017
 · 
3 min read
Bristol-Myers Squibb's Stock Topples as Kidney Cancer Drug Flunks Phase III Study
Drug Development
Why Struggling Bristol-Myers Squibb Could Take Out This Danish Biotech in Major €500M Deal
March 21, 2017
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
Heat Biologics Rockets as Lung Cancer Med Hits Mid-Stage Goals
March 21, 2017
 · 
2 min read
Drug Development
This Cheap Michigan Biotech Could Have Major Phase II Catalysts Coming
March 20, 2017
 · 
1 min read
Drug Development
Why Ionis Pharma’s Extensive And Deep Pipeline Could Get Investors’ Hearts Pumping
March 8, 2017
 · 
1 min read
Drug Development
An Expected Failure From Karyopharm’s Selinexor Doesn’t Change The Bull Thesis
March 6, 2017
 · 
1 min read
Novartis to Hold On to Its 33% Stake in Roche—For Now
Drug Development
Novartis AG Puts Cancer Hopes on 4 Star Scientists Poached From Harvard Last Year
March 1, 2017
 · 
2 min read
Kite Pharma's CAR-T Blood Cancer Candidate Succeeds in Major Study
Drug Development
Kite Pharma’s CAR-T Blood Cancer Candidate Succeeds in Major Study
February 28, 2017
 · 
3 min read
Load More
PRESS RELEASES
Press Releases
Bioxodes presents positive final Phase 2a intracerebral hemorrhage results at ESOC affirming breakthrough potential of BIOX-101
May 6, 2026
 · 
5 min read
Press Releases
Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
May 6, 2026
 · 
10 min read
Press Releases
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 6, 2026
 · 
14 min read
Press Releases
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
May 6, 2026
 · 
10 min read
Press Releases
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
 · 
12 min read
Press Releases
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week
May 6, 2026
 · 
11 min read
Press Releases
Immunocore reports first quarter 2026 financial results and provides a business update
May 6, 2026
 · 
22 min read
Press Releases
Spago Nanomedical’s Phase I/IIa study Tumorad-01 Meets a Primary Endpoint and Provides Further Visible Tumor Uptake
May 6, 2026
 · 
3 min read
Press Releases
MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
May 6, 2026
 · 
2 min read
Press Releases
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
May 6, 2026
 · 
14 min read
Press Releases
Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients
May 6, 2026
 · 
5 min read
Press Releases
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
May 6, 2026
 · 
15 min read
Press Releases
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
May 6, 2026
 · 
10 min read
Press Releases
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
May 6, 2026
 · 
6 min read
Press Releases
Nocion Therapeutics Announces Full Enrollment in Phase 2b ASPIRE Study of Taplucainium for Chronic Cough
May 5, 2026
 · 
3 min read
Press Releases
Sensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast Cancer
May 5, 2026
 · 
8 min read
Press Releases
Neuraly, Inc. Supports Phase 2 Investigator-Initiated Trial of Pegsebrenatide (NLY01) for Progressive Multiple Sclerosis
May 5, 2026
 · 
3 min read
Press Releases
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026
 · 
19 min read
Press Releases
Johnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
May 5, 2026
 · 
17 min read
Press Releases
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026
 · 
8 min read
Load More